Raymond James Financial Services Advisors, Inc. Sorrento Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.74 - $1.83 $7,030 - $17,385	-9,500 Reduced 6.58%	134,983 $120,000
Q3 2022 Oct 25, 2022	BUY	$1.51 - $2.88 $377 - $720	250 Added 0.17%	144,483 $227,000
Q2 2022 Aug 12, 2022	SELL	$1.24 - $2.33 $21,032 - $39,521	-16,962 Reduced 10.52%	144,233 $290,000
Q1 2022 May 11, 2022	BUY	$2.0 - $4.9 $24,528 - $60,093	12,264 Added 8.23%	161,195 $376,000
Q4 2021 Feb 08, 2022	SELL	$4.65 - $7.23 $307,969 - $478,842	-66,230 Reduced 30.78%	148,931 $693,000
Q3 2021 Nov 02, 2021	BUY	$7.41 - $10.99 $184,560 - $273,727	24,907 Added 13.09%	215,161 $1.64 Million
Q2 2021 Aug 11, 2021	BUY	$6.35 - $10.0 $69,329 - $109,180	10,918 Added 6.09%	190,254 $1.84 Million
Q1 2021 May 14, 2021	BUY	$7.03 - $16.51 $244,742 - $574,779	34,814 Added 24.09%	179,336 $1.48 Million
Q4 2020 Feb 12, 2021	SELL	$5.76 - $11.95 $535,714 - $1.11 Million	-93,006 Reduced 39.16%	144,522 $986,000
Q3 2020 Nov 04, 2020	BUY	$6.17 - $18.82 $1.11 Million - $3.39 Million	180,005 Added 312.93%	237,528 $2.65 Million
Q2 2020 Jul 17, 2020	BUY	$1.73 - $6.76 $77,756 - $303,834	44,946 Added 357.37%	57,523 $361,000
Q1 2020 Apr 21, 2020	BUY	$1.57 - $4.76 $3,218 - $9,758	2,050 Added 19.47%	12,577 $23,000
Q4 2019 Feb 12, 2020	SELL	$1.45 - $4.17 $2,801 - $8,056	-1,932 Reduced 15.51%	10,527 $36,000
Q1 2019 May 06, 2019	BUY	$1.86 - $5.94 $23,173 - $74,006	12,459 New	12,459 $59,000

Others Institutions Holding SRNE

# of Institutions

Shares Held

5.47M

Call Options Held

Put Options Held

View Full List

About Sorrento Therapeutics, Inc.

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

More about SRNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account